Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 15/20 | 0.36 |
| ▸ | ENPP3 | O14638 | 2/20 | 0.34 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.34 |
| ▸ | S1PR3 | Q99500 | 9/20 | 0.32 |
| ▸ | LTA4H | P09960 | 1/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5122636 | 0.76 | LOXL2 (0.41) | IRAK4S1PR1ENPP3ENPP1LTA4H | |
| SCHEMBL10282408 | 0.74 | TP53 (0.43) | IRAK4S1PR1S1PR3NOTUM | |
| SCHEMBL16217977 | 0.74 | S1PR1 (0.45) | IRAK4S1PR1S1PR3LTA4H | |
| Hydrochloric Acid SCHEMBL16210756 | 0.73 | S1PR1 (0.44) | IRAK4S1PR1S1PR3LTA4H | |
| SCHEMBL1106577 | 0.71 | NOTUM (0.64) | NOTUM | |
| SCHEMBL1106588 | 0.71 | LMNA (0.39) | — | |
| SCHEMBL4301035 | 0.62 | HRH3 (0.50) | — | |
| SCHEMBL1106592 | 0.61 | GFER (0.45) | IRAK4 | |
| SCHEMBL2707288 | 0.61 | ENPP3 (0.58) | IRAK4S1PR1ENPP3ENPP1 | |
| SCHEMBL22918669 | 0.61 | ENPP3 (0.62) | S1PR1ENPP3ENPP1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8377974-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-20120178733-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2012-07-12 | — | — | US | disclosed |
| US-8153670-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-20090298806-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2009-12-03 | — | — | US | disclosed |
| US-7521470-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298806-A1 | FACTOR XA INHIBITORS | TFPI, F12, F11 | IRAK4 3308/4885S1PR1 2160/4885ENPP3 1266/4885 |
| US-20120178733-A1 | FACTOR XA INHIBITORS | TFPI, F12, F11 | IRAK4 3308/4885S1PR1 2160/4885ENPP3 1266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.